Dow Jones

53 055,91

0,29%

Germany 40

Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

Accueil
Investir
Actions
Allemagne
TG
Novo Nordisk (NOV)
Novo Nordisk (NOV) Actualités

Novo Nordisk (NOV)

43,85

0,79

( 1,83% )

Mis à jour : 09:05:39

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 6 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 29 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 22 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 15 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Novo Nordisk A/S: IT Security incident at Novo Nordisk Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident...

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK Approval is based on results from...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care Novo Nordisk launches Wegovy® pill in the United Arab...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 1 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 26 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk...

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) Wegovy® 7.2 mg in...

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most...

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

TinOne Resources (PK)

DOWI

DJCSO1IT

DJ Commodity Index Soybe...

NASDAQ

FCQGX

Bmo Aggregate Bond Etf F...

Hidrovias DO Brasil ON

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novo Nordisk (NOV)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Novo Nordisk (NOV) Actualités

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk A/S - share repurchase programme

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk A/S - share repurchase programme

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novo Nordisk (NOV)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Novo Nordisk (NOV) Actualités

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk A/S - share repurchase programme

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk A/S - share repurchase programme

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités